EA200501131A1 - Парентеральные композиции пептидов для лечения системной красной волчанки - Google Patents
Парентеральные композиции пептидов для лечения системной красной волчанкиInfo
- Publication number
- EA200501131A1 EA200501131A1 EA200501131A EA200501131A EA200501131A1 EA 200501131 A1 EA200501131 A1 EA 200501131A1 EA 200501131 A EA200501131 A EA 200501131A EA 200501131 A EA200501131 A EA 200501131A EA 200501131 A1 EA200501131 A1 EA 200501131A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sequence
- peptide containing
- composition
- amino acid
- amino acids
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Marine Sciences & Fisheries (AREA)
- Rehabilitation Therapy (AREA)
- Toxicology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Настоящее изобретение относится к фармацевтической композиции, содержащей водный носитель; от 0,1 до 20 мг/мл композиции фармацевтически приемлемой соли a) пептида, содержащего по меньшей мере 12 и самое большое 30 следующих друг за другом аминокислот, имеющих последовательность, соответствующую (i) последовательности аминокислот, обнаруживаемой в определяющей комплементарность области (CDR) тяжелой или легкой цепи человеческого моноклонального анти-ДНК 16/6 Id-антитела, или (ii) последовательности аминокислот, обнаруживаемой в определяющей комплементарность области (CDR) тяжелой или легкой цепи патогенного моноклонального анти-ДНК-антитела, которое индуцирует ответ у мышей, подобный заболеванию системной красной волчанкой (СКВ), или b) пептида, содержащего следующие друг за другом аминокислоты, имеющие последовательность, показанную в SEQ ID NO: 8-17, или c) пептида, содержащего следующие друг за другом аминокислоты, имеющие любую последовательность из a) и b) или по меньшей мере две последовательности из последовательностей (a)(i), (a)(ii) и (b)(i) - (b)(x), или d) пептида, содержащего следующие друг за другом аминокислоты, имеющие последовательность, содержащую по меньшей мере две идентичных последовательности, включенных в (a)(i), (a)(ii) и (b)(i) - (b)(x); и усилитель растворимости, в которой и пептид, и усилитель растворимости растворены в водном носителе; и при этом композиция имеет pH от 4 до 9, и к способу ослабления симптомов СКВ у человека посредством введения эффективного количества композиции.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43991803P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000948 WO2004064787A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200501131A1 true EA200501131A1 (ru) | 2006-04-28 |
| EA009123B1 EA009123B1 (ru) | 2007-10-26 |
Family
ID=32771757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200501131A EA009123B1 (ru) | 2003-01-14 | 2004-01-14 | Парентеральные композиции пептидов для лечения системной красной волчанки |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20050008634A1 (ru) |
| EP (1) | EP1594434B1 (ru) |
| JP (2) | JP4817068B2 (ru) |
| KR (1) | KR20050100617A (ru) |
| CN (1) | CN1774259B (ru) |
| AU (1) | AU2004206842A1 (ru) |
| BR (1) | BRPI0406745A (ru) |
| CA (1) | CA2513320C (ru) |
| CO (1) | CO5640143A2 (ru) |
| CR (1) | CR7938A (ru) |
| DK (1) | DK1594434T3 (ru) |
| EA (1) | EA009123B1 (ru) |
| EC (1) | ECSP055961A (ru) |
| ES (1) | ES2606464T3 (ru) |
| IL (1) | IL169574A (ru) |
| IS (1) | IS7972A (ru) |
| MX (1) | MXPA05007549A (ru) |
| NO (1) | NO20053773L (ru) |
| NZ (1) | NZ541658A (ru) |
| WO (1) | WO2004064787A2 (ru) |
| ZA (1) | ZA200506206B (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| CA2513331A1 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| CN102281903B (zh) * | 2008-11-17 | 2013-11-13 | 弗·哈夫曼-拉罗切有限公司 | 降低大分子在生理条件下聚集的方法和配方 |
| DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
| TW201402121A (zh) * | 2012-07-12 | 2014-01-16 | Sanofi Sa | 包含１－（６－｛［６－（４－氟苯基）［１，２，４］三唑并［４，３－ｂ］嗒□－３－基］硫基｝－１，３－苯并噻唑－２－基）－３－（２－嗎啉－４－基乙基）尿素化合物之抗腫瘤組合物 |
| JP6557144B2 (ja) | 2012-10-22 | 2019-08-07 | サイデックス・ファーマシューティカルズ・インコーポレイテッド | アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法 |
| WO2014193611A1 (en) * | 2013-05-29 | 2014-12-04 | Oklahoma Medical Research Foundation | Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity |
| WO2015013669A1 (en) | 2013-07-26 | 2015-01-29 | The Regents Of The University Of California | Mps peptides and use thereof |
| WO2015095789A2 (en) * | 2013-12-20 | 2015-06-25 | The Regents Of The University Of California | Suppression of allergic lung inflammation and hyperreactivity |
| HUE063851T2 (hu) | 2014-08-22 | 2024-02-28 | Cydex Pharmaceuticals Inc | Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására |
| SG11201804961UA (en) | 2015-12-30 | 2018-07-30 | Genentech Inc | Formulations with reduced degradation of polysorbate |
| JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
| JP7242059B2 (ja) | 2017-01-05 | 2023-03-20 | イエダ リサーチ アンド ディベロプメント カンパニー リミテッド | シェーグレン症候群の治療用ペプチド |
| CN110476031A (zh) * | 2017-04-04 | 2019-11-19 | 日东电工株式会社 | 冷冻干燥体的制造方法及其制造装置 |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| WO2019108285A1 (en) * | 2017-11-30 | 2019-06-06 | Cytogel Pharma, Llc | Novel analgesic pharmaceutical formulations and uses thereof |
| CN112143707A (zh) * | 2020-09-29 | 2020-12-29 | 广东先康达生物科技有限公司 | 一种治疗自身免疫细胞的免疫细胞及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) * | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6613536B1 (en) * | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US20020054872A1 (en) * | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| IL120503A0 (en) * | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| SE9802938D0 (sv) * | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| CA2513331A1 (en) * | 2003-01-14 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
| EP1594434B1 (en) * | 2003-01-14 | 2016-09-07 | Yeda Research and Development Co. | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
| US7018891B2 (en) * | 2003-12-16 | 2006-03-28 | International Business Machines Corporation | Ultra-thin Si channel CMOS with improved series resistance |
-
2004
- 2004-01-14 EP EP04702215.7A patent/EP1594434B1/en not_active Expired - Lifetime
- 2004-01-14 AU AU2004206842A patent/AU2004206842A1/en not_active Abandoned
- 2004-01-14 BR BR0406745-2A patent/BRPI0406745A/pt not_active IP Right Cessation
- 2004-01-14 WO PCT/US2004/000948 patent/WO2004064787A2/en not_active Application Discontinuation
- 2004-01-14 CN CN2004800069872A patent/CN1774259B/zh not_active Expired - Lifetime
- 2004-01-14 JP JP2006500956A patent/JP4817068B2/ja not_active Expired - Lifetime
- 2004-01-14 NZ NZ541658A patent/NZ541658A/en unknown
- 2004-01-14 DK DK04702215.7T patent/DK1594434T3/da active
- 2004-01-14 CA CA2513320A patent/CA2513320C/en not_active Expired - Lifetime
- 2004-01-14 US US10/758,397 patent/US20050008634A1/en not_active Abandoned
- 2004-01-14 MX MXPA05007549A patent/MXPA05007549A/es not_active Application Discontinuation
- 2004-01-14 ES ES04702215.7T patent/ES2606464T3/es not_active Expired - Lifetime
- 2004-01-14 KR KR1020057013098A patent/KR20050100617A/ko not_active Application Discontinuation
- 2004-01-14 EA EA200501131A patent/EA009123B1/ru not_active IP Right Cessation
-
2005
- 2005-07-06 IL IL169574A patent/IL169574A/en active IP Right Grant
- 2005-08-03 ZA ZA200506206A patent/ZA200506206B/en unknown
- 2005-08-05 IS IS7972A patent/IS7972A/is unknown
- 2005-08-08 NO NO20053773A patent/NO20053773L/no not_active Application Discontinuation
- 2005-08-09 CR CR7938A patent/CR7938A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079328A patent/CO5640143A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005961A patent/ECSP055961A/es unknown
-
2008
- 2008-11-10 US US12/291,439 patent/US20090169559A1/en not_active Abandoned
-
2011
- 2011-03-24 JP JP2011066343A patent/JP2011173888A/ja active Pending
-
2012
- 2012-04-23 US US13/453,979 patent/US20130023485A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006517540A (ja) | 2006-07-27 |
| JP2011173888A (ja) | 2011-09-08 |
| EA009123B1 (ru) | 2007-10-26 |
| IL169574A0 (en) | 2007-07-04 |
| NO20053773L (no) | 2005-10-12 |
| WO2004064787A3 (en) | 2005-12-15 |
| CO5640143A2 (es) | 2006-05-31 |
| CR7938A (es) | 2006-05-31 |
| EP1594434A4 (en) | 2008-09-10 |
| US20130023485A1 (en) | 2013-01-24 |
| IL169574A (en) | 2015-08-31 |
| ES2606464T3 (es) | 2017-03-24 |
| NO20053773D0 (no) | 2005-08-08 |
| CN1774259B (zh) | 2011-12-28 |
| IS7972A (is) | 2006-07-15 |
| CA2513320C (en) | 2018-03-27 |
| ECSP055961A (es) | 2006-04-19 |
| AU2004206842A1 (en) | 2004-08-05 |
| JP4817068B2 (ja) | 2011-11-16 |
| CA2513320A1 (en) | 2004-08-05 |
| CN1774259A (zh) | 2006-05-17 |
| US20090169559A1 (en) | 2009-07-02 |
| KR20050100617A (ko) | 2005-10-19 |
| BRPI0406745A (pt) | 2005-12-20 |
| ZA200506206B (en) | 2006-12-27 |
| MXPA05007549A (es) | 2006-05-19 |
| US20050008634A1 (en) | 2005-01-13 |
| EP1594434B1 (en) | 2016-09-07 |
| EP1594434A2 (en) | 2005-11-16 |
| NZ541658A (en) | 2008-04-30 |
| WO2004064787A2 (en) | 2004-08-05 |
| DK1594434T3 (da) | 2017-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200501131A1 (ru) | Парентеральные композиции пептидов для лечения системной красной волчанки | |
| US20210214394A1 (en) | Alzheimer's disease treatment method | |
| ES2547230T3 (es) | Régimen dependiente de inmunoterapia en estado ApoE | |
| JP2004525922A5 (ru) | ||
| EA200400162A1 (ru) | N-(3-амино-2-гидроксипропил)замещенные алкиламидные соединения | |
| CN110506049A (zh) | 用于结合mt1-mmp的肽配体 | |
| KR101155294B1 (ko) | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 | |
| HK1154604A1 (en) | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system igm | |
| JP2002530430A (ja) | Ｃ型肝炎ウイルスｎｓ３プロテアーゼ阻害用の医薬組成物 | |
| JP2006506942A5 (ru) | ||
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| EA200501129A1 (ru) | Парентеральные композиции пептида для лечения системной красной волчанки | |
| BR0011728A (pt) | Método de inibir a agregação de proteìna amilóide e imagem de depósitos de amilóide | |
| JP2001103993A (ja) | 環状ペプチド及びセリンプロテアーゼ阻害剤 | |
| US20120010158A1 (en) | Tumor necrosis factor inhibiting peptides and uses thereof | |
| RU2012107290A (ru) | Мотилин-подобное пептидное соединение, обладающее приданной ему трансмукозальной абсорбционной способностью | |
| CN107106672B (zh) | 用于预防和治疗免疫介导性疾病的针对胞壁酰肽的单克隆抗体 | |
| EA200300900A1 (ru) | Замещенные амины (варианты), способ их получения и их применение в качестве ингибиторов транспорта глицина (варианты), композиция (варианты), промежуточный иодид и способ его получения, способ лечения пациента (варианты) | |
| KR20240053647A (ko) | 플렉신-a1의 막횡단 펩티드 길항제 및 이의 치료 용도 | |
| WO2023099669A1 (en) | Peptide inhibitors of interleukin-23 receptor | |
| RU2004103078A (ru) | Молекулы иммунного связывания, ингибирующие синцитиальное слияние клеток трофобласта | |
| AU2011226926A1 (en) | Alzheimer's disease treatment method | |
| BR9604914A (pt) | Inibidores de agregaçao de plaquetas contendo resíduos de aminoácido de cadeia lateral aminérgicos c-terminais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |